<DOC>
	<DOCNO>NCT02243150</DOCNO>
	<brief_summary>This first-in-human ( FIH ) study provide first safety , PK , PD data G1T28-1 human allow development G1T28 1 patient cancer reduce chemotherapy-induced myelosuppression .</brief_summary>
	<brief_title>Safety , Pharmacokinetic Pharmacodynamic Study CDK 4/6 Inhibitor G1T28-1</brief_title>
	<detailed_description />
	<criteria>Healthy male female volunteer , 1860 year age ; clinically significant finding report follow detailed physical examination , medical history , vital sign , clinical laboratory test , ECGs deem PI Body mass index ( BMI ) range 18 32 kg/m2 ( inclusive ) weigh least 50 kg Nonsmokers / nonusers nicotine contain product least previous 3 month Agreement use birth control study 3 month post last visit Able comply protocol requirement procedures Clinically significant abnormality find physical examination , medical history review , ECGs ( include QTcf interval &gt; 450 msec ) , vital sign laboratory test ( include positive test HIV , hepatitis B and/or C ) History serious allergic reaction medication Participated previous clinical trial investigational product last 60 day Any blood plasma donation loss blood volume exceed 500 mL within 3 month dose History drug alcohol abuse last 2 year positive test drug abuse Use systemic medication within past 2 week , include use herbal product Pregnant lactate woman Any issue , opinion PI , make subject ineligible study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>